FABP5 and neoplasm: A significant reduction in the proportion of proliferative CD8+ T cells was observed in the FABP5‐positive group compared to the FABP5‐negative group, indicating a more robust anti‐tumor immune response in the FABP5‐negative cohort (Figure9A).